Catalyst

Catalyst Biosciences is a clinical-stage firm focused on the development of novel catalytic biopharmaceutical products for human proteases.

Business Model:

Revenue: $3.2M

Employees: 11-50

Detailed Catalyst Information

Geographic Data

Catalyst headquarters map

Address: 611 Gateway Boulevard

City: South San Francisco

State: CA

Zip: 94080

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$50M

Raised Total:

$115M

Metrics

3,495,152Website Global Rank

4,060Website Monthly Traffic

Twitter Followers

Description

Catalyst Biosciences is a clinical-stage firm focused on the development of novel catalytic biopharmaceutical products for human proteases.

Contact Phone:
+16508710761

Contact Email:

Catalyst went public on 4/21/2006 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
4/21/2006

Ticker Symbol:
CBIO

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
12/2008 Post-IPO Equity 7 $40M Essex Woodlands Healthcare Partners
Sofinnova Investments
Novartis Venture Fund
Morgenthaler Ventures
Johnson &a; Johnson Development Corporation
HealthCare Ventures
Burrill &a; Company
Essex Woodlands Healthcare Partners
12/2002 Venture Round 12 $46M Societe Generale Asset Management
Nomura International
New Enterprise Associates
Genavent
EuclidSR Partners
Easton Capital
CDIB BioScience Ventures
CDC IXIS Innovation
Burrill &a; Company
Auriga Partners
Societe Generale Asset Management
Nomura International
New Enterprise Associates
Genavent
EuclidSR Partners
Easton Capital
CDIB BioScience Ventures
CDC IXIS Innovation
Burrill &a; Company
Auriga Partners
4/2014 Post-IPO Equity $5M
1/2021 Post-IPO Equity $50M
1/2015 Equity $3.2M Sofinnova Ventures
HealthCare Ventures
Morgenthaler Ventures
5/2015 Debt $1.9M
12/2017 Private Placement $10.5M
8/2013 Post-IPO Equity $400k
1/2012 Post-IPO Equity $7M
6/2015 Post-IPO Debt $1M
9/2012 Post-IPO Equity 5 $13.4M Essex Woodlands Healthcare Partners
Burrill &a; Company
Sofinnova Investments
Morgenthaler Ventures
Johnson &a; Johnson Development Corporation
Essex Woodlands Healthcare Partners
Burrill &a; Company
Sofinnova Investments
Morgenthaler Ventures
2/2015 Post-IPO Equity $3.2M
6/2000 Venture Round $30M
3/2003 Venture Round 5 $60M Bison Capital Asset Management
Castle Rock Innovations
Cogene Ventures
Jafco Life Science
Oxford Bioscience Partners
Bison Capital Asset Management
Castle Rock Innovations
Cogene Ventures
Jafco Life Science
Oxford Bioscience Partners
11/2003 Series A 2 $10.2M Sofinnova Investments
RCT BioVentures
Sofinnova Investments
RCT BioVentures
2/2006 Series B 6 $30M Morgenthaler Ventures
Sofinnova Investments
RCT BioVentures
Novartis Venture Fund
HealthCare Ventures
Burrill &a; Company
Morgenthaler Ventures
4/2013 Post-IPO Equity 6 $5.1M Essex Woodlands Healthcare Partners
HealthCare Ventures
Morgenthaler Ventures
Johnson &a; Johnson Development Corporation
Burrill &a; Company
Novartis Venture Fund
Essex Woodlands Healthcare Partners
HealthCare Ventures
Morgenthaler Ventures
Johnson &a; Johnson Development Corporation
Burrill &a; Company
Novartis Venture Fund
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research